GlassScriptPhysician profile
Tod R Reel
NPI 1619952736
$5,422.07
in general payments reported to CMS, 2019-2025
41 companies · $960 in 2025
The $960 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $184 · 2020: $511 · 2021: $867 · 2022: $780 · 2023: $1,144 · 2024: $975 · 2025: $960.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,994 · Education: $85.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,994.27 |
| Education | $85.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $983.52 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $423.34 | 2020-2025 | |
| Abbvie INC. | $409.78 | 2021-2025 | |
| Abbott Laboratories | $381.64 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2, Octrode |
| Esperion Therapeutics, INC. | $303.86 | 2020-2025 | Nexletol |
| Lilly USA, LLC | $298.41 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $284.74 | 2019-2025 | Otezla, Repatha, Evenity |
| Amarin Pharma, INC. | $272.18 | 2020-2021 | |
| Astellas Pharma US INC | $237.56 | 2019-2025 | Veozah |
| Takeda Pharmaceuticals U.S.A., INC. | $222.91 | 2021-2025 | Trintellix |
| Kowa Pharmaceuticals America, INC. | $207.94 | 2019-2023 | Livalo |
| Novartis Pharmaceuticals Corporation | $135.03 | 2019-2023 | |
| Glaxosmithkline, LLC. | $103.83 | 2020-2024 | Shingrix, Arexvy, Bexsero |
| Merck Sharp & Dohme LLC | $89.90 | 2020-2024 | Gardasil 9, Vaxneuvance, Gardasil |
| Boehringer Ingelheim Pharmaceuticals, INC. | $81.23 | 2019-2023 | Jardiance |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $69.40 | 2022-2023 | Ongentys, Ingrezza |
| Exact Sciences Corporation | $68.71 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $59.70 | 2022 | |
| Dexcom, INC. | $57.58 | 2023-2025 | Dexcom G6 Transmitter |
| Edwards Lifesciences Corporation | $55.30 | 2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Organon LLC | $55.08 | 2025 | Nexplanon |
| Medicure Pharma INC. | $54.31 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $49.77 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $47.18 | 2021 | |
| Axsome Therapeutics, INC. | $45.00 | 2024 | Auvelity |
| Dynavax Technologies Corporation | $43.21 | 2023-2025 | Heplisav-B |
| Astrazeneca Pharmaceuticals LP | $43.05 | 2024 | Farxiga, Breztri |
| Pharmacosmos Therapeutics INC. | $40.86 | 2021-2022 | |
| Phathom Pharmaceuticals, INC. | $36.89 | 2024-2025 | Voquezna |
| Bausch Health US, LLC | $31.16 | 2020-2022 | |
| Genentech USA, INC. | $29.01 | 2019-2020 | |
| Medtronic, INC. | $27.31 | 2024 | Corevalve Evolut R |
| Stryker Corporation | $25.12 | 2025 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Eisai INC. | $24.46 | 2024 | |
| Xeris Pharmaceuticals, INC. | $21.38 | 2023 | Gvoke Hypopen |
| Optinose US, INC. | $19.88 | 2020 | |
| Sanofi-Aventis U.S. LLC | $18.95 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $18.18 | 2025 | Uptravi, Opsumit |
| Evofem Biosciences, INC. | $16.61 | 2022 | |
| Shield Therapeutics INC | $14.47 | 2025 | |
| Janssen Pharmaceuticals, INC | $13.63 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tod Reel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.